Boryung Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 16, 2022 at 12:22 am EDT
Share
Boryung Corporation reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was KRW 164.33 million compared to KRW 80.6 million a year ago. Net income was KRW 15,097.83 million compared to net loss of KRW 3,046.45 million a year ago. Basic earnings per share from continuing operations was KRW 229 compared to basic loss per share from continuing operations of KRW 51 a year ago. Diluted earnings per share from continuing operations was KRW 229 compared to diluted loss per share from continuing operations of KRW 51 a year ago. Basic earnings per share was KRW 229 compared to basic loss per share of KRW 51 a year ago.
For the six months, sales was KRW 228.6 million compared to KRW 216.9 million a year ago. Net income was KRW 26,281 million compared to KRW 16,801.48 million a year ago. Basic earnings per share from continuing operations was KRW 399 compared to KRW 283 a year ago. Diluted earnings per share from continuing operations was KRW 398 compared to KRW 281 a year ago. Basic earnings per share was KRW 399 compared to KRW 283 a year ago. Diluted earnings per share was KRW 398 compared to KRW 281 a year ago.
Boryung Corp, formerly Boryung Pharm Co Ltd, is a Korea-based company principally engaged in the manufacture and sale of pharmaceutical products. The Company mainly manufactures and distributes pharmaceutical products including antihypertensive drugs, gastrointestinal disorder drugs, antibiotics, gastric ulcer drugs, oral antibiotics, anticancer drugs and antihyperlipidemic drugs, among others. The Company distributes its products in domestic and overseas markets.
BORYUNG CORPORATION 
